大活络丸

Search documents
达仁堂、雷允上等中药老字号“集体承压”!天津中成药降价划 “红黄线”,“优质优价”还能否延续
Hua Xia Shi Bao· 2025-09-25 07:59
近日,天津市医药采购中心发布《关于开展药品价格风险治理工作的通知》,将104 个存在价格风险的 中成药品推至聚光灯下。 此次天津明确划定价格管控"红黄线":药价高于同种药品最低价 3 倍但不足 5 倍的,实施黄标管理;5 倍至 10 倍的,实施红标管理;若不降价或降价后仍高于最低价 10 倍及以上,药品将直接暂停挂网。这 一刚性标准,让以往凭借品牌、工艺享受 "优质优价" 待遇的老字号药企,也切实感受到了降价压力。 临床常用药大活络丸成为此次治理的焦点,其3.5g 规格售价从每盒近200元的高价到40元左右的低价不 等。其中,同仁堂、达仁堂、雷允上三家老字号的 3.5g 规格大活络丸暂未列入天津此次治理清单,但 全国性治理态势已全面铺开 —— 今年下半年以来,广西、辽宁、黑龙江、内蒙古、陕西、宁夏等近 20 个省份已陆续加入价格治理行列。天津新政与全国 20 余省份形成政策协同,标志着中成药 "以价换量" 的行业洗牌全面加速。 售价悬殊的大活络丸遇"降价令" 本报(chinatimes.net.cn)记者于娜 北京报道 在中药领域,大活络丸是名副其实的"传统名方",用于治疗中风引发的瘫痪、肌肉萎缩、关节麻痹, ...
350年老字号青睐“买买买”
IPO日报· 2025-07-24 11:32
Core Viewpoint - Beijing Tongrentang Medical and Health Investment Co., Ltd. has officially submitted an IPO application to the Hong Kong Stock Exchange, aiming to become the fourth listed company under the Tongrentang brand following Tongrentang Co., Ltd., Tongrentang Technology, and Tongrentang Guoyao [1][2] Company Overview - Established in 2015, Tongrentang Medical and Health is a TCM medical group under the Tongrentang brand, providing TCM medical services and integrating drug and non-drug therapies [3] - The company has a history of over 350 years, with its roots tracing back to a small pharmacy in Beijing [3] - The company underwent a name change in 2019 to focus on the "healthcare" sector and completed a shareholding reform in 2024, becoming the current entity [4][5] Business Performance - As of June 24, 2025, the company has established a tiered medical service network, including 12 self-owned medical institutions and an internet hospital, making it the largest non-public TCM hospital group in China with a market share of 1.7% [5] - The company reported revenues of approximately CNY 911 million, CNY 1.153 billion, and CNY 1.175 billion from 2022 to 2024, with net profits turning from a loss of CNY 9.23 million in 2022 to profits of CNY 42.63 million and CNY 46.20 million in 2023 and 2024 respectively [6] Acquisition Strategy - The company has improved its financial performance through significant acquisitions, including the purchase of Sanxi Tang Health Hospital and Sanxi Tang Guoyao Pavilion in 2022, which contributed to 21.9%, 31.2%, and 31.8% of total revenue from 2022 to 2024 [8] - Additional acquisitions in 2024 included Shanghai Chengzhitang and Shanghai Zhonghetang, further boosting revenue growth [8] Financial Health - The company has seen an increase in debt due to cash expenditures for acquisitions, with a debt ratio rising from under 10% to over 40% during the reporting period [9] - As of April 30, 2025, the total outstanding bank loans amounted to CNY 142 million, with cash flow from operating activities showing positive growth [9] Goodwill and Valuation - The company's goodwill has significantly increased due to acquisitions, rising from CNY 26 million in 2021 to CNY 263 million in 2024, accounting for 37% of net assets [10][11]
350年老字号青睐“买买买”
Guo Ji Jin Rong Bao· 2025-07-24 09:42
Core Viewpoint - Beijing Tongrentang Medical Investment Co., Ltd. has officially submitted an IPO application to the Hong Kong Stock Exchange, aiming to become the fourth listed company under the Tongrentang brand following Tongrentang Co., Ltd., Tongrentang Technology, and Tongrentang Guoyao [1][3] Company Overview - Established in 2015, Tongrentang Medical is a TCM medical group under the Tongrentang brand, providing TCM medical services that integrate drug and non-drug therapies [3] - The company has undergone several transformations, including a name change in 2019 to focus on "medical and health" investments and a restructuring into a joint-stock company in 2024 [3][4] Business Operations - As of June 24, 2025, the company has established a tiered medical service network, including 12 owned medical institutions and one internet hospital, with a market share of 1.7% in the non-public TCM hospital sector [4] - The company primarily operates in three business segments: medical services, management services, and sales of health products, with medical services accounting for over 80% of total revenue [4] Financial Performance - Revenue figures for the years 2022 to 2024 were approximately CNY 911 million, CNY 1.153 billion, and CNY 1.175 billion, with net profits turning from a loss of CNY 9.23 million in 2022 to profits of CNY 42.63 million and CNY 46.20 million in 2023 and 2024, respectively [4][5] - The company has seen significant growth in revenue from acquisitions, particularly from the acquisition of Sanxi Tang Health Hospital and Sanxi Tang Guoyao Pavilion, which contributed 21.9% to 31.8% of total revenue from 2022 to 2024 [6] Debt and Financing - The company has increased its debt levels significantly due to multiple acquisitions, with a debt ratio rising from under 10% to over 40% during the reporting period [7][8] - As of April 30, 2025, the total outstanding bank loans amounted to CNY 142 million, with plans to use IPO proceeds for expanding medical services, repaying bank loans, and general corporate purposes [8] Goodwill and Valuation - The company's goodwill has increased substantially, from CNY 26 million in 2021 to CNY 263 million in 2024, representing 37% of net assets, indicating potential risks if future performance does not meet expectations [9]
不断提质升级、履行社会责任、扩大国际影响 激发中国品牌的澎湃动能(中国品牌日)
Ren Min Ri Bao· 2025-05-12 22:17
Group 1 - The core viewpoint emphasizes the importance of brand building for high-quality development and meeting the needs of people's better lives, as highlighted by President Xi Jinping's call for transforming Chinese manufacturing into Chinese brands [1] - The 2024 China Enterprise 500 list shows that the total revenue of the listed companies reached 110 trillion yuan in 2023, indicating a strong growth trajectory for Chinese brands [1] Group 2 - Innovation is identified as the primary driving force for development, with Chinese brands focusing on continuous innovation to enhance product differentiation and value [2] - Anta, a well-known brand in the sports goods industry, has achieved over 1 million pairs in sales within three months for its new running shoes, showcasing successful product innovation [2] - Anta aims to transform cutting-edge technology into consumer products, enhancing accessibility and quality [2] Group 3 - Technological innovation is bringing new experiences, as demonstrated by Ant Financial's launch of the Agentar platform, which provides financial institutions with a one-stop intelligent development tool [3] - Runze Technology is enhancing brand experience through technological innovation in smart computing infrastructure, supporting the digital transformation of industries [3] - Renhe Group has implemented a "smart factory" model, transitioning from traditional to intelligent pharmaceutical manufacturing, showcasing the effectiveness of digital production [4] Group 4 - Chinese brands are actively fulfilling social responsibilities and enhancing brand reputation by integrating traditional culture into their products, as seen with brands like Wuliangye and Yunnan Baiyao [4] - China Postal Savings Bank and other financial institutions are providing tailored services to small and micro enterprises, demonstrating a commitment to meet diverse consumer needs [5] Group 5 - The construction of a strong brand nation is emphasized, with a call for Chinese brands to leverage opportunities and enhance their global influence [6] - China National Nuclear Corporation is expanding international cooperation and promoting its nuclear energy brands globally, establishing partnerships with over 60 countries [7] - Moutai is enhancing its international market presence, achieving over 5 billion yuan in international sales for the first time in 2024, reflecting its growing cultural influence [7] Group 6 - China Energy Construction Group is advancing brand management by integrating brand building with operational processes, aiming to create world-class brands [8] - The quality of products is crucial for brand reputation, as demonstrated by the quality control measures implemented by Xifeng Group in its production processes [8] Group 7 - The commitment to enhancing innovation capabilities and breaking through development bottlenecks is expected to lead to the emergence of more century-old brands and iconic products in China [9]